USFDA concludes GMP inspection at Piramal Pharma’s Canada facility

02 Jun 2025 Evaluate

United States Food and Drug Administration (USFDA) has concluded general Good Manufacturing Practices (GMP) inspection at Piramal Pharma’s facility at Aurora, Canada. The inspection was conducted from May 26, 2025 to May 30, 2025. 

The inspection was completed successfully with Zero Form - 483 observations and No Action Indicated (NAI) designation. The Company remains committed to maintain the highest standards of compliance.

Piramal Pharma provides end-to-end pharma services to customers and a portfolio of differentiated pharma products across a domestic and global distribution network. 

Piramal Pharma Share Price

169.90 -2.40 (-1.39%)
01-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1720.40
Dr. Reddys Lab 1253.60
Cipla 1500.10
Zydus Lifesciences 914.50
Lupin 2103.30
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×